How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,974 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana (PubMed)

antiretroviral therapy throughout the course of the study, and similar chemotherapeutic regimens were recommended for all patients, regardless of subtype or HIV status (six to eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone; or cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). There was no difference in 1-year mortality among patients not infected with HIV and patients infected with HIV (unadjusted analysis, 52.9% v 37.1%; hazard ratio [HR], 0.73; P = .33 (...) Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana Botswana has a high prevalence of HIV infection. Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)-an AIDS-defining cancer-in the country.This study used a prospective cancer registry to identify patients with a new diagnosis of NHL reporting for specialty cancer care

Full Text available with Trip Pro

2018 Journal of global oncology

122. Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe

) may promote risk taking and undermine established social norms. However, over the course of the HIV epidemic, evidence points in a different direction. Many new and successful prevention strategies were developed in the MSM community; condom use among MSM increased as soon as AIDS was linked to sex, and AIDS activists promoted the practice through their networks. The concept of ‘negotiated safety’ also originated in the MSM community, long before the concept was given a name, defined and promoted (...) Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe www.ecdc.europa.eu Communication strategies for the prevention of HIV, STI and hepatitis among MSM in Europe TECHNICAL DOCUMENT ECDC TECHNICAL DOCUMENT Communication strategies for the prevention of HIV, STIs and hepatitis among MSM in Europe ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Irina Dinca, Piotr Wysocki, Anastasia Pharris

2016 European Centre for Disease Prevention and Control - Technical Guidance

123. Treatment of HIV-1-positive adults with antiretroviral therapy (interim update)

Treatment of HIV-1-positive adults with antiretroviral therapy (interim update) © 2016 British HIV Association _________________________________________________________________________________________________________________________ British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update) NHS Evidence has accredited the process used by the British HIV Association (BHIVA) to produce guidelines. Accreditation is valid (...) for five years from July 2012 and is applicable to guidance produced using the processes described in the British HIV Association (BHIVA) Guideline Development Manual. More information on accreditation can be viewed at www.nice.org.uk/accreditation August 2016 1 BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update) Writing Group Laura Waters Chair N Ahmed, B Angus, M Boffito, M Bower, D Churchill, D Dunn, S Edwards, C Emerson, S Fidler, †M

2017 British HIV Association

124. Improving healthcare providers? face-to-face interactions with clients living with or at-risk for HIV

) – in particular, the user’s health literacy level. Health literacy is “the ability to access, understand, evaluate and communicate information as a way to promote, maintain and improve health in a variety of settings across the life-course” (13). More than half of Canadians do not meet the minimum literacy requirements to manage their health needs (14). For persons at higher risk of HIV, and for those already living with HIV, poor health literacy interferes with their ability to fully understand HIV risk (...) Improving healthcare providers? face-to-face interactions with clients living with or at-risk for HIV RAPID RESPONSE SERVICE | #111, AUGUST 2016 1 RAPID RESPONSE SERVICE THE ONTARIO HIV TREATMENT NETWORK Question • What face-to-face interventions have proven effective in helping providers educate clients and improve their health literacy? References 1. Price-Haywood EG, Harden- Barrios J, Cooper LA. Comparative effectiveness of audit-feedback versus additional physician communication training

2016 Ontario HIV Treatment Network

125. Odefsey (emtricitabine / rilpivirine / tenofovir alafenamide) - HIV-1

Odefsey (emtricitabine / rilpivirine / tenofovir alafenamide) - HIV-1 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 28 April 2016 EMA/335723/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Odefsey International non-proprietary name: emtricitabine / rilpivirine / tenofovir alafenamide Procedure (...) ) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 January 2015. The applicant applied for the following indication: treatment of adults and adolescents aged 12 years and older weighing at least 35 kg infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load = 100,000 HIV 1 RNA copies/mL (see

2016 European Medicines Agency - EPARs

126. HIV and STI testing among Indigenous women and women who inject drugs

provided HIV testing and pre- and post-test counselling. Women’s- only needle exchange services were also provided at workshops whenever possible. Participants received grocery store gift cards for being tested, for returning for STI and HIV test results, and for attending each of the four educational workshops (10). Over the course of three years, the WORKS intervention engaged 562 participants – 68% of whom were current or former injection drug users. HIV and STI testing rates were high (...) HIV and STI testing among Indigenous women and women who inject drugs RAPID RESPONSE SERVICE | #105, MAY 2016 1 Questions What programs and services have been shown to be effective in increasing HIV and STI testing among Indigenous women and women who inject drugs? References 1. Orchard TR, Druyts E, McInnes CW , Clement K, Ding E, Fernandes KA et al. Factors behind HIV testing practices among Canadian Aboriginal peoples living off-reserve. AIDS Care 2010 March;22(3):324-31. 2. Lally MA

2016 Ontario HIV Treatment Network

127. Public health guidance on HIV and STI prevention among men who have sex with men

Public health guidance on HIV and STI prevention among men who have sex with men ECDC GUIDANCE HIV and STI prevention among men who have sex with men www.ecdc.europa.eu ECDC GUIDANCE HIV and STI prevention among men who have sex with men ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Anastasia Pharris and Andrew J. Amato-Gauci with technical input from Paloma Carrillo-Santisteve, Tarik Derrough, Erika Duffell, Marco Fonzo, Yvan (...) consultants, formerly Public Health Agency of Sweden). Invaluable input was received from the guidance expert panel, which included the following persons: Rigmor C Berg, Norwegian Knowledge Center for Health Services, Norway, Torsten Berglund, Public Health Agency of Sweden (Folkhälsomydigheten), Hans Blystad, Norwegian Institute of Public Health, Department of Infectious Disease Epidemiology, Norway, Michael Bochow, Consultant, Germany, Jordi Casabona i Barbarà, Center for HIV/STI Epidemiological Studies

2015 European Centre for Disease Prevention and Control - Public Health Guidance

128. Reminder systems for people living with HIV

Reminder systems for people living with HIV Reminder systems for people living with HIV | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Reminder systems for people living with HIV Reminder systems for people living with HIV , Questions What types of telephone, computer and other app-based interventions have been effective in reminding people living with HIV to attend medical appointments and adhere to antiretroviral medications? What types of telephone, computer and other (...) app-based interventions have been effective in reminding people living with HIV to test/retest for STIs and subsequently notify their partners when testing positive? Key take-home messages Text messaging, smart phone applications and cell phone counselling are all effective in promoting adherence to antiretroviral therapy (1-4). Text messaging and smart phone reminders are more effective if they are personal in nature, and if they evoke or require a response from the participant (2;4-6). Text

2015 Ontario HIV Treatment Network

129. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost (...) Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? | Sexually Transmitted Infections by The case of India has been seen as a model of an intelligent and integrated use of data for an evidence-based response to the HIV/AIDS epidemic ( ). Avahan, the India HIV/AIDS

2018 Sexually Transmitted Infections blog

130. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost (...) Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? | Sexually Transmitted Infections by The case of India has been seen as a model of an intelligent and integrated use of data for an evidence-based response to the HIV/AIDS epidemic ( ). Avahan, the India HIV/AIDS

2018 Sexually Transmitted Infections blog

131. Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. (PubMed)

Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. Mortality associated with in-utero HIV infection rises rapidly within weeks after birth. Very early infant diagnosis of HIV (VEID)-testing within 2 weeks of birth-followed by immediate initiation of antiretroviral therapy has potential to avert mortality associated with in-utero transmission. However, our understanding of acceptability and feasibility (...) of VEID is limited.VEID was piloted in an observational prospective cohort of HIV-positive pregnant women and their infants in 13 Lesotho health facilities. Between March-July 2016, semi-structured interviews were conducted with HIV-positive women attending 6-week or 14-week postnatal visits and health workers (HWs) in 8 study facilities in 3 districts as well as with district and central laboratory staff. Interview themes included acceptability of birth and subsequent HIV testing and early treatment

Full Text available with Trip Pro

2018 PLoS ONE

132. Malaria care-seeking behaviour among HIV-infected patients receiving antiretroviral treatment in South-Eastern Nigeria: A cross-sectional study. (PubMed)

in self-medication; 39.2% went to drug shops, and only 22.6% visited HIV/AIDS care centres. Almost 40% waited more than 24 hours before initiating treatment. Most (60.3%), reported taking recommended artemisinin-based combination treatments (ACT) but a significant minority took only paracetamol (25.6%) or herbal remedies (3.5%). Most (80%) finished their chosen course of treatment; and completion of treatment was significantly associated with the frequency of suspected malaria occurrence (p = 0.03 (...) Malaria care-seeking behaviour among HIV-infected patients receiving antiretroviral treatment in South-Eastern Nigeria: A cross-sectional study. This study assesses malaria prevention and treatment behaviour among people living with HIV/AIDS (PLWHA) in Owerri, South Eastern Nigeria. Although Nigeria bears one of the world's largest burdens of both malaria and HIV, there is almost no research studying how co-infected patients manage their care. We systematically sampled 398 PLWHA receiving care

Full Text available with Trip Pro

2019 PLoS ONE

133. Properties of a brief assessment tool for longitudinal measurement of cognition in people living with HIV. (PubMed)

Properties of a brief assessment tool for longitudinal measurement of cognition in people living with HIV. Mild cognitive impairment is common in chronic HIV infection and there is concern that it may worsen with age. Distinguishing static impairment from on-going decline is clinically important, but the field lacks well-validated cognitive measures sensitive to decline and feasible for routine clinical use. Measures capable of detecting improvement are also needed to assess interventions (...) . The objective of this study is to estimate the extent of change on repeat administration of three different forms of a brief computerized cognitive assessment battery (B-CAM) developed for assessing cognitive ability in the mildly-impaired to normal range in people living with HIV. We hypothesized no change over a six-month period in people on effective antiretroviral therapy.102 HIV+ individuals completed a set of computerized cognitive tasks on three occasions over a six-month period. Rasch analysis

Full Text available with Trip Pro

2019 PLoS ONE

134. Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambézia Province, Mozambique. (PubMed)

the benefits of joining CASGs earlier in one´s treatment course. Finally, greater efforts should be made to accelerate the scale-up of viral load capacity and HIV resistance monitoring. (...) Individual factors associated with time to non-adherence to ART pick-up within HIV care and treatment services in three health facilities of Zambézia Province, Mozambique. Mozambique has made significant gains in addressing its HIV epidemic, yet adherence to visit schedules remains a challenge. HIV programmatic gains to date could be impaired if adherence and retention to ART remains low. We investigate individual factors associated with non-adherence to ART pick-up in Mozambique.This

Full Text available with Trip Pro

2019 PLoS ONE

135. "I am still negative": Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa. (PubMed)

"I am still negative": Female sex workers' perspectives on uptake and use of daily pre-exposure prophylaxis for HIV prevention in South Africa. Women remain highly vulnerable to HIV infection in sub-Saharan Africa, with female sex workers (FSWs) facing some of the highest rates of HIV. Oral pre-exposure prophylaxis (PrEP) has the potential to reduce new infections among populations at highest risk and end-user perspectives of actual use in 'real-world' settings are critical to informing PrEP (...) implementation. This paper presents findings from serial in-depth interviews (IDIs) conducted with FSW participants during the course of the Treatment And Prevention for Sex workers (TAPS) Demonstration Project in South Africa, exploring the lived experiences and perceptions of taking up and using PrEP. This research provides insight into risks and responsibilities facing FSWs perceived as prominent drivers in taking up and using PrEP, how PrEP was adopted to mitigate risk or ameliorate realities

Full Text available with Trip Pro

2019 PLoS ONE

136. HIV-1 Group O Origin, Evolution, Pathogenesis, and Treatment: Unraveling the Complexity of an Outlier 25 Years Later. (PubMed)

HIV-1 Group O Origin, Evolution, Pathogenesis, and Treatment: Unraveling the Complexity of an Outlier 25 Years Later. Twenty-five years ago, an aberrant HIV-1 (now classified as HIV-1 group O) was described from a Cameroonian HIV patient living in Belgium. The epicenter of group O was later found to be in Central Africa, overlapping with the geographical location of the central chimpanzees (Pan troglodytes troglodytes) and western gorillas (Gorilla gorilla), the likely original hosts of group O (...) . Although the prevalence of group O has remained low at 1-2% in Cameroon, some European countries (France, Spain, Belgium) with strong colonial ties to Central Africa have reported the highest prevalence out of Africa. The sequence diversity between HIV-1 group O and M strains is huge, reaching 50 and 30% in the envelope and pol, respectively. This diversity has hindered diagnosis, monitoring, and treatment of group O-infected patients. Due to the intrinsic presence of the C181 mutation in group O, more

2020 AIDS reviews

137. Antiretroviral Therapy in Primary HIV-1 Infection: Influences on Immune Activation and Gut Mucosal Barrier Dysfunction. (PubMed)

of infection indicate the crucial role of HIV-1-specific responses and non-specific immune activation in disease progression. The clinical benefit of early antiretroviral therapy has been somewhat disappointing, with the exception of a small group of patients exhibiting sustained control of HIV replication after transient antiretroviral therapy, designated as post-treatment controllers. This review focuses on the influences of antiretroviral therapy initiated early or very early in the course of infection (...) Antiretroviral Therapy in Primary HIV-1 Infection: Influences on Immune Activation and Gut Mucosal Barrier Dysfunction. The recent advances in the understanding of primary HIV-1 infection and the development of well-tolerated antiretroviral therapies have highlighted the potential impact of early treatment initiation on immune responses and gut mucosal barrier dysfunction. Immunological and virological assessments in the blood as well as in gut-associated lymphoid tissues during the early phase

2020 AIDS reviews

138. The prevalence and process of pediatric HIV disclosure: A population-based prospective cohort study in Zimbabwe. (PubMed)

the virus to others (i.e. "full disclosure"). Older children were more likely to know their status. Among the non-disclosed caregivers at baseline, nearly 60% of these children learned their HIV status over the course of the 12-month study period, but only 17.1% learned how they were infected and that they can transmit the virus to others. Most caregivers were satisfied with their child's disclosure experience. Caregivers who had not disclosed their child's HIV status to the child worried (...) The prevalence and process of pediatric HIV disclosure: A population-based prospective cohort study in Zimbabwe. The objective of this study was to estimate the prevalence of pediatric HIV disclosure in rural Zimbabwe and track the process of disclosure over time.We recruited a population-based sample of 372 caregivers of HIV-positive children ages 9 to 15 to participate in a survey about disclosure. Using data from this cross-sectional sample, we then identified a prospective cohort of 123

Full Text available with Trip Pro

2019 PLoS ONE

139. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. (PubMed)

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. The Thai Phase III Trial of ALVAC-HIV and AIDSVAX B/E showed an estimated vaccine efficacy (VE) of 31% to prevent acquisition of human immunodeficiency virus (HIV). Here we evaluated the effect of vaccination on disease progression after infection.CD4(+) T-cell counts and HIV viral load (VL) were measured serially (...) and per protocol (n = 90) cohorts. Estimated VEP (mITT) was15.8% (-21.9, 41.8) at 60 months postinfection. There was weak evidence of lower VL and higher CD4(+) count at 60 and 66 months in the vaccine group. Lower mucosal VL was observed among vaccine recipients, primarily in semen (P = .04).Vaccination did not affect the clinical course of HIV disease after infection. A potential vaccine effect on the genital mucosa warrants further study.

Full Text available with Trip Pro

2013 Journal of Infectious Diseases

140. HIV Trafficking between Blood and Semen during Early Untreated HIV Infection (PubMed)

HIV Trafficking between Blood and Semen during Early Untreated HIV Infection Understanding the dynamics of HIV across anatomic compartments is important to design effective eradication strategies. In this study, we evaluated viral trafficking between blood and semen during primary HIV infection in 6 antiretroviral-naive men who have sex with men.Deep sequencing data of HIV env were generated from longitudinal blood plasma, peripheral blood mononuclear cells, and seminal plasma samples (...) . The presence or absence of viral compartmentalization was assessed using tree-based Slatkin-Maddison and distance-based Fst methods. Phylogeographic analyses were performed using a discrete Bayesian asymmetric approach of diffusion with Markov jump count estimation to evaluate the gene flow between blood and semen during primary HIV infection. Levels of DNA from human herpesviruses and selected inflammatory cytokines were also measured on genital secretions collected at baseline to evaluate potential

Full Text available with Trip Pro

2017 Journal of acquired immune deficiency syndromes (1999)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>